The estimated Net Worth of Robert James Rudelius is at least 632 千$ dollars as of 1 January 2020. Robert Rudelius owns over 13,000 units of Axogen stock worth over 632,008$ and over the last 13 years Robert sold AXGN stock worth over 0$.
Robert has made over 4 trades of the Axogen stock since 2011, according to the Form 4 filled with the SEC. Most recently Robert exercised 13,000 units of AXGN stock worth 35,750$ on 1 January 2020.
The largest trade Robert's ever made was exercising 20,000 units of Axogen stock on 8 September 2017 worth over 70,000$. On average, Robert trades about 3,344 units every 185 days since 2011. As of 1 January 2020 Robert still owns at least 47,591 units of Axogen stock.
You can see the complete history of Robert Rudelius stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is 13631 PROGRESS BOULEVARD, SUITE 400, ALACHUA, FL, 32615.
Over the last 14 years, insiders at Axogen have traded over 73,805,978$ worth of Axogen stock and bought 504,297 units worth 3,119,117$ . The most active insiders traders include James E Deerfield Mgmt L.P....、Guido J Neels、Karen L. Zaderej. On average, Axogen executives and independent directors trade stock every 21 days with the average trade being worth of 455,132$. The most recent stock trade was executed by John Johnson on 1 September 2024, trading 11,904 units of AXGN stock currently worth 158,085$.
it's time to rethink nerve repair! axogen (nasdaq: axgn) is a medical products company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. people suffer traumatic injuries or undergo surgeries that impact the function of their peripheral nerves daily. damage may cause loss of function and feeling. axogen is bringing the science of nerve repair to life with its avance® nerve graft which axogen believes is the first and only commercially available allograft for bridging nerve discontinuities, axoguard® nerve connector, a coaptation aid allowing for close approximation of severed nerves, and axoguard® nerve protector that protects nerves during the healing process.
Axogen executives and other stock owners filed with the SEC include: